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Over the last three decades acute liver failure (ALF) has been
transformed from a rare and poorly understood condition with
a near universally fatal outcome, to one with a well characterized
phenotype and disease course. Complex critical care protocols are
now applied and emergency liver transplantation (ELT) is an
established treatment option. These improvements in care are
such that the majority of patients may now be expected to sur-
vive (Fig. 1). Key features of the condition have changed dra-
matically over time, with a remarkable fall in the incidence of
cerebral edema and intracranial hypertension, a much feared
complication. In this review, we summarize the current under-
standing of key aspects of the classiﬁcation, pathophysiology
and management of ALF, and discuss the foreseeable challenges
that will need to be addressed for further improvements to be
achieved.
 2014 European Association for the Study of the Liver. Published
by Elsevier B.V. Open access under CC BY-NC-ND license.Acute liver failure: Phenotype, epidemiology and outcome
Acute liver failure (ALF) was initially deﬁned nearly 50 years
ago as the simultaneous appearance of hepatic encephalopathy
and coagulation defects in the setting of an acute liver insult of
any kind and in the absence of pre-existing liver disease [1].
Over the years, deﬁnitions have varied in regard to durationJournal of Hepatology 20
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is characterized by a relatively speciﬁc latency. A remarkably
consistent central pattern of clinical signs and symptoms char-
acterizes all causes of ALF, regardless of etiology when severe
liver injury evolves over days or weeks: prolonged prothrombin
time/INR (PT/INR), decline in mental function, peripheral
vasodilation, features of the systemic inﬂammatory response
syndrome, and ultimately multi-organ failure [2]. This section
will emphasize the role of etiology in epidemiology and out-
comes; despite the relatively uniform clinical presentation,
the different causes of ALF are associated with remarkably dif-
ferent outcomes [3]. Thus, the outcome is deﬁned by the eti-
ology, which must be determined for prognostic assessment
and where possible, to apply appropriate cause-speciﬁc
therapy.
Role of etiologies worldwide
Over the past half century, the relative frequency of causes of
ALF has evolved, with hepatitis A and B declining in incidence,
and paracetamol (acetaminophen) increasing, at least in Wes-
tern Europe and the United States [4]. The differences in eti-
ology between developing and developed countries are well
characterized, Europe and the United States feature a high
incidence of paracetamol toxicity leading to ALF along with
drug-induced liver injury due to prescription agents, less com-
mon but equally as important. By contrast, South Asia and
Hong Kong have a higher incidence of hepatitis viruses,
speciﬁcally hepatitis E in Pakistan and hepatitis B in Hong
Kong, as well as in Australia, with fewer cases of drug-in-
duced liver injury observed at least in the developing world
[5,6].
Data from the United States collected over a 17-year period
highlights the critical effect of paracetamol usage on ALF over this
time, comprising nearly half of all cases over this long period
(Fig. 2). In parallel to paracetamol overdoses, idiosyncratic
drug-induced liver injury is one of the most common discernible
causes, whilst indeterminate etiology (cause not discernible after
extensive evaluation) continues to be a sizable patient group. In
the United Kingdom paracetamol remains the predominant eti-
ology of ALF, but an exponential rise in severe poisoning was
effectively controlled by the restriction imposed on sales of the
drug in 1998 [7].15 vol. 62 j S112–S120
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Fig. 1. Hospital survival for patients with ALF with encephalopathy of grade 3
and above, King’s College Hospital, UK 1973–2008, (N = 2095). Error bars are
95% conﬁdence intervals. p <0.0001. Source: Bernal et al. J Hepatol 2013; 59:74–
80 [18].
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Fig. 2. Etiology of ALF in the USA: US ALFSG Adult Registry 1998–2014,
(N = 2102). APAP, paracetamol; DILI, non-paracetamol drug-induced liver injury;
HBV, Hepatitis B virus; HAV, Hepatitis A infection. Source: US ALFSG unpublished
data October 2014.
JOURNAL OF HEPATOLOGYDuration of illness
Important in understanding the clinical features and prognosis in
ALF is the relationship of injury pattern, determined by etiology,
and course of illness and its duration [8]. Varying names have
been applied but the terms hyperacute, acute and sub-acute are
often used [8]. The period of active injury in paracetamol and
ischemic cases may be measured in hours, and it is self-limited.
With this overall pattern of illness (very short), there is rapid onset
and offset, and a ﬁnite period of necrosis. These patients are char-
acterized as having a ‘hyperacute’ pattern, and, in many cases, a
rapid recovery despite massive multi-organ failure. This pattern
differs greatly from most other forms of ALF, usually termed
‘acute or sub-acute’, wherein the pattern of injury evolves over
1–4 weeks, and is not self-limited, but long lasting. Drug-induced
liver injury, hepatitis B, autoimmune hepatitis and most indeter-
minate cases will have a sub-acute pattern and a worse survival.
The liver tests results differs markedly, with the hyperacute
patients characterized by low bilirubin levels and strikingly high
aminotransferases, characteristic of cell necrosis as the primary
pathogenetic mechanism (Table 1). By contrast, sub-acute
patients have lower serum aminotransferases and higher serum
bilirubin values, consequent upon a more gradual liver injury
and thus longer time interval to reach a stage of ALF with severe
hyperbilirubinemia. The pathogenic mechanisms likely vary
among the etiologies, but apoptosis and activation of the adaptive
immune response are important here.
Speciﬁc therapies
It follows that therapy where possible should be directed at the
speciﬁc etiology [2,9]. However, once ALF ensues, liver damageJournal of Hepatology 2015may be established and it may be too late for speciﬁc therapies
to be effective. For example, N-acetylcysteine (NAC) is the known
antidote for paracetamol overdose, and is given even days after
onset of injury despite uncertainty as to its efﬁcacy when given
late [10]. There is also uncertainty relating to the use of NAC
for non-paracetamol liver injury. An apparent survival beneﬁt
from its use has been shown in early stage ALF for non-paraceta-
mol etiologies, but not for those with advanced coma grades [11].
In most ALF settings, NAC appears to be safe and is administered
because of possible, not certain, beneﬁt once severe injury is
already established [9]. Other agents of uncertain beneﬁt include
nucleoside analogues for hepatitis B, and corticosteroids for ALF
resulting from autoimmune hepatitis; prolonged steroid use
may predispose to infection and preclude deﬁnitive transplanta-
tion [12,13].
Conclusion
Establishing the correct etiologic diagnosis is vital for the
management of ALF as it unfolds, on account that diagnosis
impacts therapy choice as well as prognosis. Most prognostic
scores include speciﬁcation of etiology and/or time of illness
[12,14]. Efforts are now underway to ensure that the etiology
is correctly diagnosed in a timely fashion using measures
beyond the usual hepatitis and autoimmune serologies, e.g.,
use of paracetamol-cys adduct measurements to conﬁrm or
deny that paracetamol is the cause of injury [15]. In some
instances, the original diagnosis needs to be re-examined in
this light.
Key Points 
• Survival for patients with ALF has improved dramatically 
in the last three decades, reflecting advances in medical 
critical care and the use of transplantation
• Establishing the correct etiologic diagnosis remains 
vital to management of evolving ALF, since diagnosis 
impacts therapy choices as well as prognostic 
assessment
• Supportive medical care is most effective when 
commenced early, addressing all aspects of the multi-
organ dysfunction and failure seen in ALF
• The incidence of cerebral edema and intra-cranial 
hypertension has fallen markedly over time and is 
likely related to earlier disease recognition and better 
initial treatment, control of body temperature, plasma 
tonicity, systemic hemodynamics and early use of renal 
replacement therapy
• Results for emergency liver transplantation in ALF have 
improved and in the long-term are close to those for an 
elective procedure. The sensitivity of prognostic criteria 
remains to be improved and makes for difficulties in 
transplant selection
• For paracetamol (acetaminophen) induced ALF, 
survival with medical care now approaches that for liver 
transplantation, raising questions of transplant benefitvol. 62 j S112–S120 S113
Table 1. Cumulative demographic, laboratory and outcome data by etiology of ALF. ALFSG Adult Registry, USA 1998–2014, n = 2000.
APAP
n = 916
DILI
n = 220
Indeterminate
n = 245
HAV
n = 36
HBV
n = 142
All others
n = 441
Age (median years) 37 46 39 49 43 45
Sex (% F) 76 69 59 44 44 71
Jaundice to coma (median days) 1 12 11 4 8 7
HE grade ≥3 (%) 53 35 48 56 52 38
ALT (median IU) 3773 640 865 2275 1649 681
Bilirubin (median μmol/L) 74 339 361 210 315 238
Transplanted (%) 9 40 42 33 39 32
Spontaneous survival (%) 66 24 22 50 21 31
60 72 55 58
APAP, paracetamol; DILI, non-paracetamol drug-induced liver injury; HBV, hepatitis B virus; HAV, Hepatitis A infection; HE, hepatic encephalopathy. Source; ALFSG
unpublished data October 2014.
ReviewPathophysiology of encephalopathy and cerebral edema (CE);
why has incidence of CE fallen?Overall survival (%) 73 58The development of disordered brain function, manifested as
hepatic encephalopathy, is a key element of the multisystem ill-
ness that accompanies ALF. In patients with advanced
encephalopathy, CE may also evolve and cause death due to cere-
bral herniation [16,17]. Unexpectedly, the incidence of CE has
declined markedly over the last three decades and in many cen-
tres it is now seen in fewer than a quarter of patients, even when
high-grade encephalopathy is present [18,19] (Fig. 3A and B). This
may reﬂect both improvements in preventative medical care and
the consequences of the use of ELT, which rapidly restores liver
function in those patients at most risk of CE. However, once CE
has developed in ALF it is still associated with very poor survival
and complex critical care management is required [2,18].
Pathophysiology
The pathophysiology of both hepatic encephalopathy and brain
edema in ALF are multi-factorial and its better characterization
may provide some explanation of the changes in incidence of0 
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Fig. 3. Changing prevalence of cerebral edema (CE) in ALF. (A) Clinical
evidence of CE in patients with ALF by presentation of illness. Japan 1998–2009,
(N = 1094). Source: Oketani M et al., Hepatol Res 2013;43:97–105 [19]. Acute
<10 d, sub-acute 10 d-8 wk. (B) Clinical evidence of CE-related Intracranial
Hypertension (ICH) in patients with ALF and encephalopathy of grade 3 and
above, Kings College Hospital UK 1973–2008, (N = 1549). Error bars are 95%
conﬁdence intervals. p <0.0001. Source: Bernal et al. J Hepatol 2013; 59:74–80
[18].
S114 Journal of Hepatology 2015CE and herniation (Fig. 4). Release of material from dying cells
within the liver and a ‘‘spill-over’’ of pro-inﬂammatory mediators
from the splanchnic area to the systemic circulation results in
cardiovascular instability; resembling vasodilatory septic shock,
with low systemic vascular resistance, high cardiac output and
a low arterial blood pressure that result in a decline in cerebral
perfusion pressure [2,20].
This reduction in arterial pressure would normally not affect
the brain due to a strict regulation of cerebral blood ﬂow. This
regulation is, however, absent in patients with ALF, and episodes
of arterial hypotension may directly result in cerebral hypoperfu-
sion and induce, or worsen CE [21]. Systemic inﬂammatory med-
iators may affect the brain by altering the cerebral endothelial
function and may cross the blood–brain barrier (BBB) and induce
CE through microglial activation [22]. However, the most impor-
tant pathogenic factor for development of encephalopathy and CE
is the release of ammonia from the failing liver due to a lack of
urea synthesis. Experimental and clinical studies over the last
three decades document that acute hyperammonemia speciﬁcal-
ly affects the brain, as ammonia easily crosses the BBB, and have
characterized its role as a potent neurotoxin [23].
Once ammonia has crossed the BBB, glutamine synthetase
(GS), primarily found in astrocytes, catalyses’ glutamate to glu-
tamine through utilization of ammonia. This process of detoxiﬁ-
cation results in the accumulation of glutamine that acts as an
organic osmolyte and increases astrocyte volume, resulting in
metabolic disturbances by a dysequilibrium of biochemical path-
ways promoting a shortage of glutamate. A decline in glutamate
concentration can only partly be prevented by amination of a-ke-
toglutarate to glutamate but may, in severe persistent cases of
hyperammonemia, result in substrate depletion of the tricar-
boxylic acid cycle where a-ketoglutarate is an essential metabo-
lite. Furthermore, ammonia may inhibit two rate limiting
enzymes; pyruvate dehydrogenase, and a-ketoglutarate dehy-
drogenase. The imminent substrate depletion and partial enzyme
inhibition compromise overall oxidative metabolism and lead to
depletion of energy-rich phosphate compounds (ATP and GTP)
and accumulation of lactate [24–26]. In addition, ammonia both
induces oxidative and nitrosative stress by formation of free radi-
cals which may in turn result in mitochondrial permeability tran-
sition (MPT), i.e., a state with imminent ‘‘power failure’’ of the
orchestrating astrocytes [23,24].vol. 62 j S112–S120
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Fig. 4. An integrated model of the pathogenesis of cerebral edema (CE) in ALF. Potential interventions are depicted in light blue circles, and those in clinical use with
darker blue outline. ALF, acute liver failure; CBF, cerebral blood ﬂow; COX, cyclooxygenase; CVVHF, continuous venovenous hemoﬁltration; MPT, mitochondrial
permeability transition; NaCl, saline; RNOS, reactive nitrogen and oxygen species; TCA, tricarboxylic acid; TNF, tumor necrosis factor. (Modiﬁed and reproduced with
permission from authors and publisher: Bjerring PN et al. The brain in acute liver failure. Metab Brain Dis 2009; 24:5–14).
JOURNAL OF HEPATOLOGYAs a consequence of these processes water is taken up into the
astrocytes and they swell. The compensatory mechanisms nor-
mally initiated to counteract astrocyte volume changes act
through restoration of the osmotic balance between the intracel-
lular and extracellular milieu, by the combined activation of chlo-
ride and potassium channels, and later by release of organic
osmolytes including myo-inositol and taurine. These mechanisms
are highly energy dependent and require optimal metabolic con-
ditions to operate. Consequently the failure of the astrocytes
‘‘regulatory volume decrease’’ mechanism results in their swel-
ling and leads to CE. The development of hyponatraemia, which
is common in ALF, will only worsen such brain swelling as the
associated fall in serum osmolality creates an osmolar gradient
that favors water movement into the cells [2,27].
Approaches to neurological care
The complex interplay between changes in haemodynamics,
immune response, ammonia trafﬁcking, osmotic cell load, oxida-
tive metabolism and plasma tonicity are all components that
need to be considered when managing ALF patients to secure
brain viability. To achieve this, restoration of circulating volume,
prevention of sepsis, inotropic and vasopressor support, and
sedation and mechanical ventilation are cornerstones in the man-
agement of these patients. The place of invasive intracranial pres-
sure monitoring remains uncertain and controversial with little
evidence to suggest clinical beneﬁt, albeit with a low rate of com-
plications [28]. Early initiation of continuous renal replacement
therapy with or without addition of hypertonic saline may help
to decrease the level of circulating ammonia and restore the nor-
mal osmotic gradient across the BBB by keeping the tonicity high
[2]. Since systemic inﬂammation may result from a spill-over ofJournal of Hepatology 2015pro-inﬂammatory mediators from the failing liver, total
hepatectomy and the use of various liver assist devices as a
bridge to transplantation have been utilized and reported to con-
trol brain edema, however such effects may relate to lowering of
body temperature.
Lowering the body temperature slows down the rate of
metabolic processes that are involved in development of CE, and
the induction of mild hypothermia can be lifesaving in patients
awaiting ELT [29]. It remains, however, unclear if ALF patients
who are not liver transplantation candidates will beneﬁt from this
kind of intervention, with retrospective studies showing little evi-
dence of improved survival [2,30]. A prospective randomized, con-
trolled study of controlling intracranial pressure by lowering the
body temperature prophylactively in ALF patients has been car-
ried out and the ﬁnal results are pending [31]. In ALF with
manifesting intracranial hypertension, the anti-inﬂammatory
non-steroidal anti-inﬂammatory drug (NSAID) indomethacin has
been shown to prevent CE and further intracranial hypertension
[32]. This effect is also seen after the administration of diclofenac,
indicating that NSAIDs may be effective by blocking the cyclooxy-
genases. However, the prophylactic use of these NSAIDs in
patients’ needs further investigation as theymay also induce renal
dysfunction.
The role of glutamine-induced MPT in the development of
clinically overt CE in ALF patients introduces the possibility of
new therapeutic approaches in achieving neuroprotection by
use of MPT-inhibitors such as L-histidin and cyclosporine [23].
There are indications that the use of hemoﬁltration, liver assist
devices or plasma exchange may have a role in increasing
ammonia clearance, and modulate the immune system and pre-
vent development of multi-organ failure and brain edema
[2,33].vol. 62 j S112–S120 S115
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Fig. 5. Correlation between continuous venovenous hemoﬁltration ultraﬁl-
tration rate and ammonia clearance in patients with liver failure. Source:
Slack AJ et al. Liver Int 2014:34:42–48 [43].
Review
Medical management
Supportive care
The approach to medical supportive care delivered to patients
with ALF must be comprehensive, addressing the multiple organ
systems that may be involved. Certain etiologies of ALF have the
potential for recovery through native liver regeneration and
resolution of extra-hepatic organ failure. The overall aims of sup-
portive care are thus to optimize conditions for hepatic regen-
eration, and to anticipate and prevent complications, whilst
continually assessing native liver recovery and potential need
for transplantation [2]. The success of these approaches to care
are reﬂected in the progressive improvements seen in survival
both with and without transplantation [18].
Where possible, potential precipitants should be actively
treated as this may mitigate the severity of subsequent hepatic
and extra-hepatic organ dysfunction or failure. These treatments,
along with more generic supportive care, should commence as
early as possible to maximize clinical beneﬁt. The majority of
patients with ALF are ﬂuid depleted at presentation and require
ﬂuid resuscitation. The exception may be patients with hypoxic
hepatitis, where ﬂuid overload maybe a contributing factor to
hepatic congestion and liver injury, necessitating venous off load-
ing and inotropic support [34]. The ﬂuid choice at initial presen-
tation would normally be a crystalloid, with normal saline being
the most frequently used solution. Despite marked perturbation
of laboratory tests of coagulation, functional testing may reveal
no major bleeding tendency or even a prothrombotic state. Loss
of hepatic synthesis of procoagulant factors is paralleled by that
of anticoagulants and thus a balanced hemostatic defect often
exists [35]. Overt bleeding is uncommon and routine administra-
tion of coagulation factors is not indicated.
The level of monitoring required will depend upon the clinical
situation and needs to be responsive to changing physiology.
Patients with coagulopathy and encephalopathy or renal dys-
function should be monitored in a critical care environment with
full access to invasive cardiovascular monitoring, alongside
echocardiographic and ultrasound support to assess ﬂuid respon-
siveness and requirement for vasoactive medication. Easy access
to ventilatory support is required as encephalopathy may pro-
gress rapidly, with most centres intubating and ventilating those
patients who develop anything more than low-grade
encephalopathy.
Monitoring of arterial blood gases will allow tracking of sodi-
um, chloride and lactate, close control of which is essential in the
provision of optimal care. Sodium levels should be maintained at
the high end of normal with aims between 145 and 150 mmol/L
following development of high-grade encephalopathy [36].
Monitoring of lactate provides a composite assessment of pro-
duction and clearance. Initial hyperlactataemia often relates usu-
ally to ﬂuid depletion and is frequently reversible; subsequent
lactate production is likely driven by catecholamine-induced
muscle production alongside impaired liver clearance [37]. Sus-
tained elevations in lactate after restoration of circulating volume
provides important prognostic information and may help identify
candidates for transplantation [38,39]. Magnesium and phos-
phate should be actively monitored and maintained in the nor-
mal range.
A systemic inﬂammatory response is a marker of signiﬁcance
reﬂecting severity of liver insult, development of extra-hepaticS116 Journal of Hepatology 2015organ dysfunction and risk of death [40–42]. It may or may not
be driven by sepsis; decision making in respect of antibiotic
and antifungal medication should be undertaken on the basis of
clinical assessment. Most patients with encephalopathy in asso-
ciation with coagulopathy or renal failure will be managed with
antibiotics, often in combination with antifungal agents.
Renal dysfunction is common in ALF and may be poorly repre-
sented by the standard measures of creatinine or urea. In patients
with ALF the role of the kidney in ammonia clearance becomes
increasingly important and arterial ammonia levels should be
closely monitored. Early institution of renal replacement therapy
facilitates biochemical and temperature control, ﬂuid balance and
controls circulating ammonia levels. Clinically signiﬁcant ammo-
nia clearance can be achieved in adult patients with hyperam-
monaemia utilizing conventional continuous hemoﬁltration,
with a clearance rate correlating closely with that of hemoﬁltra-
tion (Fig. 5) [43].
Management of the airway is required in those with high-
grade encephalopathy or more rarely in the management of
hypoxaemia [44]. Standard ventilator techniques should be
undertaken to limit tidal volume and plateau pressure whilst
ensuring normocarbia. Sedative agents would normally comprise
intravenous propofol and an opiate.
Function of the gastro-intestinal tract is often impaired and
pancreatitis should be excluded [45]. Enteral nutrition may be
tolerated, and if instituted, arterial ammonia should be moni-
tored as hyperammonemia may be triggered by moderate enteral
protein loads in those patients with major acute hepatic insufﬁ-
ciency. If enteral nutrition is not tolerated later introduction of
intravenous feeding may be considered [46]. Normoglycaemia
should be monitored, and if not maintained 20% and 50% dextrose
should be used to achieve normoglycaemia without causing
hyponatraemia.
Extracorporeal liver support devices
Extracorporeal Liver Assist Devices (ECLAD) have long been
sought as a means to temporarily replace lost liver function
whilst awaiting deﬁnitive transplantation or native liver regen-
eration. However, despite decades of research and millions of
euros of speculative investment, no device has yet been shown
to be of deﬁnitive beneﬁt to patients with ALF.vol. 62 j S112–S120
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Fig. 6. Patient survival after liver transplantation for ALF, Europe 1988–2009.
Source: Germani et al. J Hepatol 2012; 57:288–296 [50].
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An effective ECLAD could be of great clinical utility in ALF: as
discussed above, in some etiologies of disease, hepatic regen-
erative potential exists despite initially profound hepatic insufﬁ-
ciency. ECLAD could form a rapidly available ‘off the shelf’ device
to stabilize hepatic function as an adjunct to other forms of sup-
portive therapy. In doing so it might increase the proportion of
patients surviving with medical management alone. When the
threshold beyond which successful hepatic regeneration cannot
occur has been crossed and transplantation is required, such
devices could temporarily augment liver function and stabilize
clinical condition whilst a graft is awaited.
These devices can be broadly categorized as biological or non-
biological; the former seek to utilize the synthetic and detoxify-
ing metabolic activity of human or non-human cells upon the
blood or plasma of patients with ALF, and the latter is ‘detoxiﬁca-
tion’ through a variety of ﬁltration or absorption mechanisms.
Some devices have shown initial promise with evidence of
biochemical improvement and case series have suggested clinical
beneﬁt. In consequence, some devices have been in clinical use
without deﬁnitive conﬁrmation of efﬁcacy; the rarity, severity
and heterogeneity of ALF make it a uniquely difﬁcult and expen-
sive condition upon which to perform randomized clinical trials,
particularly so when further complicated by the logistics of pro-
viding a complex and functional device at the point of need. Trials
of some of these devices have now been performed in ALF but
without deﬁnitive evidence of beneﬁt.
The Molecular Adsorbent Recirculating System (MARS) device
has been in use for both ALF and Acute on Chronic Liver Failure
(AOCLF) in various conﬁgurations since 1993 and aims to remove
toxic molecules through plasma dialysis across an albumin-por-
ous exchange membrane and absorption into a series of binding
columns. Its use in patients with liver failure is associated with
biochemical improvements, though these may not be sustained
[47]. An RCT in ALF has now been published: in a French multi-
centre study 102 patients fulﬁlling poor prognosis criteria were
randomized to receive MARS therapy or standard of care; in those
treated with MARS the median cumulative duration of therapy
was 10 hours [33]. On both per-protocol and intention-to-treat
analysis, and when stratiﬁed for etiology there was no signiﬁcant
differences in survival. Sixty-six percent of patients underwent
ELT, at a median of 16 hours after randomization, curtailing the
duration of treatment and making deﬁnitive conﬁrmation of lack
of efﬁcacy impossible.
Biological devices present greater technical and logistical
issues in their development and clinical application. Nonetheless,
several generations of device have been developed and applied to
patients over the last three decades – with only one relatively
recent RCT [48]. This trial used the HepatAssist device which uti-
lizes porcine hepatocytes in a bioreactor perfused with the
patient’s plasma. In a study of 171 patients with ALF or post
transplantation primary graft non-function, the device showed
no survival advantage over standard care on intention-to-treat
analysis, though a post hoc assessment of patients with good
prognosis etiologies gave some indications of improved survival
[48].
A new generation of biological devices is shortly to begin clin-
ical trials and may yet show the real practical beneﬁts and
improved patient outcome that current devices have failed to
deliver. Other novel therapies also have promise, with initial
reports of a RCT of High Volume Plasma Exchange suggesting a
mortality beneﬁt from its use [49].Journal of Hepatology 2015Evolution of liver transplantation for ALF and issues of
candidate selection
The introduction of ELT for the treatment of patients with ALF in
the mid-1980s was a notable achievement and many desperately
ill patients who would have previously died of the condition owe
their lives to it. In the King’s College Hospital (KCH) series of over
3300 patients with ALF, the overall survival rate in 2008, includ-
ing those transplanted, was 62.2% compared with 16.7% in 1973
[18] (Fig. 1). Medical care has also improved and questions are
now being raised as to the additional beneﬁt of transplantation
and of the criteria used in the selection of patients for
transplantation.
Transplantation outcomes
ELT in such desperately sick patients would be expected to carry
a high operative and post-operative complication rate and the
recently published data of the European Liver Transplant Registry
show just how survival results have improved, although 1 year
survival is still around 10% less than for elective transplants
(Fig. 6) [50]. Characteristically, the survival curve has an initial
steep dip over the ﬁrst 3 months reﬂecting operative and early
post-operative complications and is then almost levelled, unlike
that seen with cirrhosis or primary hepatocellular carcinoma
where there is a steady decline due to recurrence of original dis-
ease or the effects of co-morbidity in an older age group. Because
of the ﬂat curve, the 5 and 10 year survival ﬁgures; of 75% and
72% for the last 5 year period analysed compare favourably with
those for elective transplants. Independent risk factors for mor-
tality comprise recipient age of >50 years, male gender, donor
age >60 years and the use of incompatible or reduced sized graft.
These risk factors can make a striking difference to ﬁrst year mor-
tality; 57% for a male more than 50 years old receiving an organ
from a donor aged 60 years or more [50].
Clinical deterioration in ALF, particularly of the hyperacute
category, can be extraordinarily rapid and survival is heavily
dependent on time taken to obtain an organ. A study from the
KCH group showed that of the 74 cases placed on the waiting list
that did not get transplanted, 52 died before an organ becamevol. 62 j S112–S120 S117
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Fig. 7. Non-transplanted survival in patients with ALF by presentation of
illness, Japan 2004–09 (N = 352). Disease onset to encephalopathy; Acute
<10 days, Sub-acute 10 d-8 wk, Late onset 8–24 weeks. Source: Oketani M
et al., Hepatol Res 2013; 43:97–105 [19].
Review
available and 15 became too ill for the transplant within a medi-
an of 2 days [51]. The importance of the prioritization in donor
allocation accorded to ALF in most countries cannot be over
stressed.
Prognostic and selection criteria
An important question is whether the better results frommedical
care alter the value of the criteria used in transplant selection and
the overall transplant beneﬁt. This is particularly so for the parac-
etamol hyperacute category of cases as O’Grady has recently dis-
cussed [52]. The overall hospital survival rate for paracetamol-
related ALF and grade 3 or 4 encephalopathy in the KCH series
was 66%; three-quarters of these patients had not received a liver
transplant but still had a survival rate of 52%. A prospective study
of 275 paracetamol-related ALF transplants carried out by the
USA ALF group included 72 patients on the waiting list who
had a survival rate of 73%, increasing to only 78% after liver trans-
plantation [52].
Not only survival beneﬁt but the quality of life after the trans-
plant has to be considered. In the ﬁrst of two recent studies,
social problems post-transplant as a cause of death or graft fail-
ure including non-adherence to immunosuppression were nearly
10% higher in the paracetamol overdose cases than for other eti-
ologies [50]. In the second study, the non-transplanted sponta-
neous survivors had the greatest decrease in quality of life with
high rates of psychiatric disease and substance abuse raising fur-
ther questions as to the appropriateness of ELT for this category
of ALF [53].
The question of whether better medical care is altering the
values of prognostic indices of long-established criteria used in
transplant selection is a difﬁcult one. The KCH Criteria ﬁrst
described in 1989 which has different modellings for paraceta-
mol and non-paracetamol categories continue to be very widely
used [14]. One recent addition is measurement of blood lactate,
which at high levels proves to be an excellent prognostic marker
of severe liver injury from paracetamol. Its speciﬁcity for both
paracetamol and non-paracetamol cases as initially described
was high, as shown by high positive predictive values of 95%
and 100% respectively [54,39]. Negative predictive values, how-
ever, in the original series and subsequent studies are lower, indi-
cating that for patients not fulﬁlling the criteria who were not
therefore listed, there was still a signiﬁcant chance of dying.
The pooled meta-analysis of the KCH Criteria carried out in
2010 showed speciﬁcity to be high for paracetamol ALF at 95%
[55], and less for the non-paracetamol category at 81% [56]. Sen-
sitivity was relatively poor for both groups; 58% for paracetamol
and 68% for non-paracetamol. Interestingly, sensitivity for the
non-paracetamol group was found to be less in studies post
2005 as compared with earlier ﬁndings [56].
Not surprisingly, a number of other prognostic and scoring
systems have been instigated with the desire to obtain more opti-
mal sensitivity as well as retaining speciﬁcity. MELD was found to
outperform KCH Criteria in 1 of 4 studies, and transplant selec-
tion based on SOFA and APACHE II scores was shown to be better
than both of these [57,58]. The USA ALF Study Group reported
that the addition of the apoptosis marker M30 of the CK18 mole-
cule improved the sensitivity of the KCH Criteria to 86% but speci-
ﬁcity was reduced to 65% [59]. Serial measurement of liver
volumes on CT, comparing the 5 day result with that on admis-
sion, provided an objective index [60], and in another study theS118 Journal of Hepatology 2015ﬁnding of a liver volume of less than 1000 ml had a predicted
mortality of 97% [61]. The best approach almost certainly is a
dynamic one, as utilized in the new assessment models devel-
oped in the UK and India [62,63]. The sequential daily assessment
of prognostically important variables has shown predictive accu-
racy superior to the standard KCH Criteria [62,63].
The indication for a transplant is clearer in the indeterminate,
seronegative hepatitis or sub-acute liver failure category as med-
ical care alone has so far not substantially improved the chances
of spontaneous recovery (Fig. 7). A single centre experience
showed excellent early and long-term survival ﬁgures for trans-
plantation; 81% at 12 months and 73% at 5 years [64]. A high
BMI for the donor was the most important predictor of death
after transplantation, presumably related to steatosis of the graft.
Most of the deaths in this group occur within the ﬁrst 2 months
from sepsis and multi-organ failure. A timely transplant which
means an early decision on the need for it, is essential.Conclusion
In conclusion, we have accumulated an extraordinary amount of
knowledge about the pathophysiology of the main causes of ALF
over the past 40 years. Gaps remain, particularly, for instance, in
the late onset indeterminate category and more investigative
research needs to be directed to this group of patients. Over the
same 40 years we have seen extraordinary advances in patient
care for what was once considered a uniformly fatal diagnosis.
Improving survival rates even further will be dependent on gain-
ing a better understanding of disease progression and the evolu-
tion of multi-organ failure. We need to reﬁne and improve
extracorporeal liver support which will give the time necessary
for spontaneous recovery to occur, and to help in maintaining
the very sick patient until an organ is available. Key to all of this
and indeed dependent on it, is early recognition of the patients
with ALF and their referral to a specialist liver centre where all
the expertise and facilities, including liver transplantation, are
available for treating what is still a rare disease but one if which
poorly treated remains a killer.Conﬂict of interest
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